ENDPOINTS NEWS24 分钟
J&J buys In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet
John­son & John­son is ac­quir­ing In­tra-Cel­lu­lar Ther­a­pies for $14.6 bil­lion in the biggest biotech M&A trans­ac­tion ...
ENDPOINTS NEWS52 分钟
Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, following J&J's recent entry into STAT6 space ...